文献速递脑血管病

静脉阿替普酶与最佳药物治疗对轻型卒中患者的比较:系统综述与Meta分析

Intravenous Alteplase Versus Best Medical Therapy for Patients With Minor Stroke: A Systematic Review and Meta-Analysis.
PubMed 文献 · Stroke · 2024-03-11

该系统综述与Meta分析纳入20项高质量研究共13397例急性轻型缺血性卒中患者,比较静脉溶栓(IVT)与最佳药物治疗(BMT)的疗效与安全性。结果显示IVT在90天改良Rankin量表评分0-1分(OR 1.10,95%CI 0.89-1.37)和0-2分(OR 1.16,95%CI 0.95-1.43)、死亡率、复发卒中及复发缺血性卒中方面与BMT无显著差异,但早期神经功能恶化(OR 1.81,95%CI 1.17-2.80)、症状性颅内出血(OR 7.48,95%CI 3.55-15.76)和出血转化(OR 4.73,95%CI 2.40-9.34)风险增加。在无致残性缺损或使用抗血小板药物的亚组中,IVT相比BMT未显示优势。

要点

  • IVT与BMT在90天改良Rankin量表评分0-1分(OR 1.10,95%CI 0.89-1.37)和0-2分(OR 1.16,95%CI 0.95-1.43)无显著差异。
  • IVT组症状性颅内出血风险显著高于BMT组(OR 7.48,95%CI 3.55-15.76)。
  • 在无致残性缺损或使用抗血小板药物的亚组中,IVT相比BMT未显示优势。

核心结论

  • IVT未显著改善急性轻型缺血性卒中患者的功能预后,且相比BMT增加症状性颅内出血风险。
  • 在无致残性缺损或使用抗血小板药物的患者中,IVT可能不优于BMT。

研究设计与样本

  • 系统综述与Meta分析,纳入20项高质量随机对照试验和观察性研究,共13397例急性轻型缺血性卒中患者(NIHSS评分0-5分)。
  • 检索PubMed、Embase、Cochrane Library和Web of Science数据库从建库至2023年8月10日的文献。
  • 主要结局为90天改良Rankin量表评分0或1分(优秀功能结局),采用比值比(OR)计算总体及预设亚组的关联。
  • 研究注册于PROSPERO(CRD42023445856)。

主要发现

  • IVT组与BMT组在改良Rankin量表评分0-1分(OR 1.10,95%CI 0.89-1.37)和0-2分(OR 1.16,95%CI 0.95-1.43)无显著差异。
  • IVT组与BMT组在死亡率(OR 0.67,95%CI 0.39-1.15)、复发卒中(OR 0.89,95%CI 0.57-1.38)和复发缺血性卒中(OR 1.09,95%CI 0.68-1.73)无显著差异。
  • IVT组相比BMT组,早期神经功能恶化(OR 1.81,95%CI 1.17-2.80)、症状性颅内出血(OR 7.48,95%CI 3.55-15.76)和出血转化(OR 4.73,95%CI 2.40-9.34)风险增加。
  • 在无致残性缺损或使用抗血小板药物的亚组中,改良Rankin量表评分0-1分的比较结果保持不变。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The efficacy of thrombolysis (IVT) in minor stroke (National Institutes of Health Stroke Scale score, 0-5) remains inconclusive. The aim of this study is to compare the effectiveness and safety of IVT with best medical therapy (BMT) by means of a systematic review and meta-analysis of randomized controlled trials and observational studies. METHODS: We searched the PubMed, Embase, Cochrane Library, and Web of Science databases to obtain articles related to IVT in minor stroke from inception until August 10, 2023. The primary outcome was an excellent functional outcome, defined as a modified Rankin Scale score of 0 or 1 at 90 days. The associations were calculated for the overall and preformulated subgroups by using the odds ratios (ORs). This study was registered with PROSPERO (CRD42023445856). RESULTS: A total of 20 high-quality studies, comprised of 13 397 patients with acute minor ischemic stroke, were included. There were no significant differences observed in the modified Rankin Scale scores of 0 to 1 (OR, 1.10 [95% CI, 0.89-1.37]) and 0 to 2 (OR, 1.16 [95% CI, 0.95-1.43]), mortality rates (OR, 0.67 [95% CI, 0.39-1.15]), recurrent stroke (OR, 0.89 [95% CI, 0.57-1.38]), and recurrent ischemic stroke (OR, 1.09 [95% CI, 0.68-1.73]) between the IVT and BMT group. There were differences between the IVT group and the BMT group in terms of early neurological deterioration (OR, 1.81 [95% CI, 1.17-2.80]), symptomatic intracranial hemorrhage (OR, 7.48 [95% CI, 3.55-15.76]), and hemorrhagic transformation (OR, 4.73 [95% CI, 2.40-9.34]). Comparison of modified Rankin Scale score of 0 to 1 remained unchanged in subgroup patients with nondisabling deficits or compared with those using antiplatelets. CONCLUSIONS: These findings indicate that IVT does not yield significant improvement in the functional prognosis of patients with acute minor ischemic stroke. Additionally, it is associated with an increased risk of symptomatic intracranial hemorrhage when compared with the BMT. Moreover, IVT may not have superiority over BMT in patients with nondisabling deficits or those using antiplatelets.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Lv T, Nguyen TN, et al. Intravenous Alteplase Versus Best Medical Therapy for Patients With Minor Stroke: A Systematic Review and Meta-Analysis. Stroke. 2024. PMID: 38465591. doi:10.1161/STROKEAHA.123.045495

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。